ARTICLE SUMMARY:
Growth is the name of the game in the diabetes device market as companies with automated insulin delivery systems, including Insulet, Tandem Diabetes Care, and Medtronic, push into the type 2 space, while Abbott and Dexcom, suppliers of continuous glucose monitoring devices, eye even broader opportunities with newly cleared over-the-counter CGM systems. Much of the ongoing innovation was on display at the American Diabetes Association meeting, held recently in Orlando, FL.
The 2024 meeting of the American Diabetes Association (ADA), held in June in Orlando, FL, once again showcased the future direction of diabetes device technology, with an emphasis on expanding options and access for people across the diabetes care continuum.
With continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems now considered standard of care for people with type 1 diabetes (T1D), manufacturers are working to bring these technologies to a wider range of people who could benefit. Both AID and CGM suppliers are targeting the much larger type 2 diabetes (T2D) market, but CGM companies hope to go even further, into prediabetes and beyond. And there are some newly cleared over-the-counter CGM devices that could help them do just that.
Expanding Into Type 2 Diabetes
At this year’s ADA, device companies continued to highlight the potential benefits that can be achieved by offering CGM and AID systems to people with T2D. Among the data presented were final outcomes from Insulet’s SECURE-T2D pivotal trial of its Omnipod 5 (O5) tubeless, on-body AID system in T2D, and preliminary results from Medtronic’s Phase I pivotal study testing the 780G AID system in T2D. In addition, more evidence was presented that CGMs can benefit people with T2D, even those not on insulin, and they appear to offer an additive benefit for those taking a GLP-1 receptor agonist (GLP-1RA) drug, such as Ozempic or Mounjaro.
The potential market for these technologies in T2D dwarfs the much smaller type 1 segment. But growth opportunities remain in both populations, since only about a quarter of all people with diabetes are currently achieving optimal glucose control (an A1c < 7%) and both the pump and CGM markets remain underpenetrated.
